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Abstract
Background: Docosahexaenoic acid (DHA) is a natural compound with anticancer and anti-angiogenesis activity
that is currently under investigation as both a preventative agent and an adjuvant to breast cancer therapy. However, the
precise mechanisms of DHA’s anticancer activities are unclear. It is understood that the intercommunication between
cancer cells and their microenvironment is essential to tumor angiogenesis. Exosomes are extracellular vesicles
that are important mediators of intercellular communication and play a role in promoting angiogenesis. However,
very little is known about the contribution of breast cancer exosomes to tumor angiogenesis or whether exosomes can
mediate DHA’s anticancer action.
Results: Exosomes were collected from MCF7 and MDA-MB-231 breast cancer cells after treatment with DHA. We
observed an increase in exosome secretion and exosome microRNA contents from the DHA-treated cells. The expression
of 83 microRNAs in the MCF7 exosomes was altered by DHA (>2-fold). The most abundant exosome microRNAs
(let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic
activity. These microRNAs were also increased by DHA treatment in the exosomes from other breast cancer lines
(MDA-MB-231, ZR751 and BT20), but not in exosomes from normal breast cells (MCF10A). When DHA-treated MCF7 cells
were co-cultured with or their exosomes were directly applied to endothelial cell cultures, we observed an increase in the
expression of these microRNAs in the endothelial cells. Furthermore, overexpression of miR-23b and miR-320b in
endothelial cells decreased the expression of their pro-angiogenic target genes (PLAU, AMOTL1, NRP1 and ETS2)
and significantly inhibited tube formation by endothelial cells, suggesting that the microRNAs transferred by exosomes
mediate DHA’s anti-angiogenic action. These effects could be reversed by knockdown of the Rab GTPase, Rab27A, which
controls exosome release.
Conclusions: We conclude that DHA alters breast cancer exosome secretion and microRNA contents, which leads to the
inhibition of angiogenesis. Our data demonstrate that breast cancer exosome signaling can be targeted to inhibit tumor
angiogenesis and provide new insight into DHA’s anticancer action, further supporting its use in cancer therapy.
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Background
Docosahexaenoic acid (DHA, 22:6) is a long-chain omega-
3 polyunsaturated fatty acid and the main component
of dietary fish oil that has many health benefits, including
anticancer activity [1, 2]. The anticancer properties of DHA
have been demonstrated both in vitro [3, 4] and in vivo
[5–7]. Importantly, DHA is cytotoxic to tumor cells, with
little or no effects on normal cells [3, 8]. Currently, several
clinical trials are evaluating DHA supplementation for
breast cancer therapy and management (clinicaltrials.gov).
These studies underline the potential value of DHA as both
a safe preventative agent and as an adjuvant to therapy.
One of the reported anticancer mechanisms of DHA is
the ability to suppress tumor angiogenesis. For example,
a DHA-supplemented diet suppresses tumor angiogenesis
as measured by microvessel counts in a breast cancer nude
mouse model [9] and this observation was confirmed in a
murine mammary tumor model also fed a fish oil diet
[10]. The anti-angiogenic activity of DHA is also de-
scribed in a human colon cancer model system [11], a
fibrosarcoma implantation model in Fischer 344 rats [12],
and in human umbilical cord vein endothelial cells [13].
The cellular mechanisms of how DHA suppresses tumor
angiogenesis remain unclear. Traditionally, vascular endo-
thelial growth factor (VEGF), which is secreted from cancer
cells in response to hypoxia, is considered the key regulator
of tumor angiogenesis and current strategies to inhibit
tumor angiogenesis are primarily focused on targeting the
VEGF pathway [14]. However, recent studies have demon-
strated that other cellular signaling molecules, such as exo-
somes, also mediate tumor angiogenesis [15–17].
Exosomes are small (50–100 nm) vesicles that have
recently been recognized as important mediators of inter-
cellular communication. They carry lipids, proteins,
mRNAs and microRNAs that can be transferred to a
recipient cell [18, 19]. Tumor cells have been shown to se-
crete exosomes in greater amounts than normal cells [20],
thus allowing the transfer of tumor-associated signaling
molecules to surrounding cells [21–23]. Importantly, the
microRNAs in secreted exosomes can be transferred to a
recipient cell where they affect post-transcriptional gene
regulation [24]. Cancer cell-derived microRNAs can be
transferred via exosomes to endothelial cells where they
induce pro-angiogenic effects [15, 16]. These studies
underline the role tumor-derived exosomes can play in
the tumor microenvironment and in promoting tumor
angiogenesis. However, very little is known about the
contents and secretion of breast cancer exosomes or
ways to manipulate or reduce their influence on cancer
progression. In this study we sought to determine how
DHA might alter the secretion and contents of breast
cancer exosomes thereby suppressing tumor angiogen-
esis and progression, which may lead to a better under-
standing of breast cancer biology and novel strategies
targeting intercellular communication for breast cancer
therapy.
Results
DHA increases the small RNA contents of breast cancer
exosomes
Human breast cancer MCF7 and MDA-MB-231 cells
were grown in cell culture medium supplemented with
exosome-depleted serum for 3 days and treated with
100 μM DHA for 24 h. Whole exosomes were collected
from the conditioned medium of DHA-treated and un-
treated MCF7 cells. The exosomes were fixed and nega-
tively stained for visualization by electron microscopy. We
found exosomes of the typical ~100 nm diameter in both
samples (Fig. 1a), (MDA-MB-231 exosomes not shown).
The isolated exosomes had detectable CD63 expression, a
well-established marker for exosomes, by immunogold
labeling and imaging by electron microscopy (Fig. 1b) and
by western blot (Fig. 1c). Total RNA was isolated from the
exosomes and a RNA profile was generated. We found
that the RNA isolated from the MCF7 exosomes was pri-
marily small RNA of less than 1,000 nt and typically
absent of ribosomal RNA as compared to the total cellular
RNA (Fig. 1d). These observations are similar to previous
reports [25, 26]. However, in the DHA treated exosome
RNA sample we observed an increase in the small RNA
content of <200 nt (see Fig. 1d, lower right panel). These
results indicate that DHA increases the small RNA con-
tent of breast cancer exosomes.
DHA increases microRNA levels in breast cancer cells and
exosomes
To further determine if DHA increases the small RNA con-
tent of breast cancer secreted exosomes, a small RNA li-
brary was prepared from equal quantities of total RNA
isolated from the DHA-treated and untreated MCF7 exo-
somes and cells. The resulting cDNA library was sequenced
and the reads were mapped onto the human genome (Build
36, Mar 2006) and intersected with known mature micro-
RNAs (mirBase, v13; www.mirbase.org). Overall, DHA treat-
ment increased the number of mature microRNAs detected
in the MCF7 cells and exosomes. In the cells, 387 micro-
RNAs were detected (at least 1 read) in control MCF7
cells versus 412 detected in the DHA-treated MCF7
cells (increase of 25 microRNAs). In the exosomes, 196
microRNAs were detected in the control exosomes ver-
sus 209 detected in the DHA-treated exosomes (in-
crease of 13 microRNAs) (Additional file 1). These
results are consistent with the increase in small RNA
content observed in the RNA profile (Fig. 1d). Twenty-
six cellular microRNAs were changed (1.5-fold or greater)
by DHA-treatment (19 up-regulated and 7 down-regulated)
(see control cell vs. DHA cell in Additional file 1). Three
microRNAs (miR-1246, 204-fold; miR-451, 135-fold; and
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miR-127-3p, 6-fold) were preferentially encapsulated into
the exosomes and found at very low levels in the cellular
content, which is in agreement with a recent study [27] (see
control cell vs. control exosome in Additional file 1). In the
DHA-treated exosomes 91 mature microRNAs were de-
tected (at least 1 read), 83 of which were changed by 2-fold
or greater compared to the untreated exosomes and 22 of
these microRNAs were present at greater than 1,000 copies
in at least one condition; these 22 microRNAs are listed in
Table 1. Our results demonstrate that DHA alters the
microRNA profile of MCF7 cell-derived exosomes.
DHA increases let-7a, miR-21, miR-23b, miR-27b, and
miR-320b levels in exosomes from other breast cancer
cell lines, but not from normal breast cells
To determine if the effects of DHA on exosome micro-
RNA levels are specific to only MCF7 breast cancer cells
or whether DHA can increase the exosome microRNA
levels in normal mammary epithelial cells or other breast
cancer types, we cultured a normal mammary epithelial
cell line (MCF10A), an ER-positive luminal line (ZR-75-1)
and two triple-negative basal-like breast cancer lines
(BT20 and MDA-MB-231). Exosomes were isolated
from the conditioned media after DHA treatment and
total RNA was extracted from the control and DHA-
treated exosomes. The expression of 5 of the most
abundant microRNAs (let-7a, miR-21, miR-23b, miR-27b,
and miR-320b) detected in the DHA-treated MCF7 exo-
somes was measured in the exosomes from the other
breast cell lines by qRT-PCR. As shown in Fig. 2, DHA
treatment increased the expression of all 5 of these micro-
RNAs in the DHA-treated exosomes as compared to con-
trol exosomes, with the exception of let-7a and miR-21 in
MDA-MB-231 cells. In contrast, DHA-treatment did not
Fig. 1 Isolation and molecular characterization of exosomes shed from breast cancer cells. a Exosomes were isolated from the conditioned media
of control or treated MCF7 cells (100 μM DHA for 24 h) using the Exoquick Reagent, fixed, whole-mounted on coated Formvar grids, negatively stained
and visualized by electron microscopy (Hitachi H-7600). Left column, 40,000×; right column 100,000×. Images are representative of three experiments. b
Immunogold labeling and electron microscopy of human CD63 (10 nM gold particles) on exosomes isolated from MCF7 cells (100,000×). cWestern blot
analysis of the exosome marker CD63 (30–60 kDa) in exosomes shed from MCF7 and MDA-MB-231 cells. Exosome lysates were run under non-reducing
conditions. d RNA Agilent Bioanalyzer profile of total RNA extracted from control and DHA treated MCF7 cells and their purified exosomes. The peak at
25 nt is a lower marker standard and is indicated on the upper left image. In the exosome preparations the RNA is predominantly <1,000 nucleotides in
length, with a large peak noted in the small RNA range of the DHA-treated exosomes and the 28S and 18S ribosomal subunit RNAs (as indicated on upper
left image) are notably absent from both treated and untreated exosome preparations
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increase the expression of these microRNAs in the exo-
somes from MCF10A cells; rather microRNA expression
was decreased by DHA-treatment in these exosomes.
These results indicate that the effect of DHA on the
microRNA content of their exosomes is specific to cancer
cells and is not dependent on the breast cancer subtype.
DHA increases exosome secretion from breast cancer cells
To determine if exosome secretion is altered by DHA
we measured CD63 expression in DHA-treated and con-
trol exosomes secreted from MCF7 and MDA-MB-231
cell lines by western blot. We found increased levels of
CD63 protein in the DHA-treated exosome preparations
from both cell lines (Fig. 3a). In order to monitor exo-
some production and measure their release we generated
MCF7 and MDA-MB-231 cell lines stably expressing the
exosome marker CD63 tagged with GFP (CD63-GFP)
(Additional file 2). The MCF7 and MDA-MB-231 CD63-
GFP cells were grown in cell culture media supplemented
with exosome-depleted FBS and treated with 100 μM DHA
for 24 h. Exosomes were isolated from the conditioned
media by ultracentrifugation and suspended in PBS. The
presence of GFP in the isolated exosomes was measured
by fluorescent spectrometry. We observed a significant
increase in exosome secretion from DHA treated versus
untreated cell cultures (Fig. 3b), while the cell number was
unaffected by DHA treatment (Fig. 3c). These results indi-
cate that DHA increases exosome secretion from breast
cancer cell lines.
Breast cancer exosomes are absorbed by endothelial cells
and DHA treatment inhibits endothelial cell tube formation
without affecting VEGF levels
We then asked whether the anti-angiogenesis activity
of DHA could be due to the DHA-induced changes in
exosome secretion and microRNA contents that we
had observed. First, to determine if breast cancer exo-
somes can be readily transferred to endothelial cells we
cultured the endothelial cell line EA.hy926 on matrigel
in the presence of purified exosomes isolated from MCF7
cells that were pre-labeled with the nucleic acid binding
dye, acridine orange (AO). The purified AO-labeled
exosomes were applied to EA.hy926 cells and imaged by
fluorescent microscopy. The presence of AO-exosomes in
endothelial cells was observed as early as 2 h (not shown)
and 24 h (Fig. 3d) indicating that breast cancer exosomes
are readily transferred to endothelial cells. Then to deter-
mine if tube-formation (in vitro angiogenesis) by endothe-
lial cells is affected by the DHA-induced changes in the
breast cancer exosomes, equal volumes of exosomes
isolated from control and DHA-treated MCF7 cells
were applied to cultures of EA.hy926 plated on matrigel.
Tube formation by EA.hy926 cells was significantly
inhibited by the exosomes purified from DHA-treated
MCF7 cells compared to those purified from control
MCF7 cells (Fig. 3e). These results suggest that DHA
suppresses tumor angiogenesis via modulating breast
cancer cell-derived exosome contents. This conclusion
was further supported by the observation that DHA
and troglitazone (a PPARγ ligand) did not alter VEGF
secretion, while clofibrate (a PPARα ligand) reduced
VEGF secretion from MCF7 cells (Fig. 3f ).
microRNAs released by DHA-treated breast cancer cells
are transferred to endothelial cells
Several of the most abundant microRNAs in the DHA-
treated exosomes have known activity in targeting endothe-
lial cells and suppressing angiogenesis, such as miR-21 [28],
miR-23b [29], miR-27b [30] and miR-320b [31]. Therefore,
it is highly likely that these microRNAs contribute to the
anti-angiogenesis activity of DHA. To test whether these
microRNAs can be absorbed by endothelial cells, MCF7
cells were co-cultured with EA.hy926 cells for 24 h and the
Table 1 DHA increases microRNA expression levels in MCF7
exosomes
microRNA Mapped reads Fold-change P-value
Control DHA
miR-23b 205.5 1064.8 5.18 1.0E-20
miR-378 333.3 1510.2 4.53 1.0E-20
let-7f 2949.3 11386.4 3.86 1.0E-20
miR-21 10853.1 41786.2 3.85 1.0E-20
let-7a 4748.9 17764.0 3.74 1.0E-20
miR-182 2044.0 6986.1 3.42 1.0E-20
miR-151-3p 522.1 1760.1 3.37 1.0E-20
miR-27b 4082.4 13189.9 3.23 1.0E-20
let-7e 472.1 1521.1 3.22 1.0E-20
miR-27a 4032.4 12896.6 3.20 1.0E-20
let-7c 449.9 1434.2 3.19 1.1E-16
miR-365 888.7 2824.9 3.18 1.0E-20
miR-320b 516.6 1553.7 3.01 1.0E-20
let-7i 783.2 2335.9 2.98 1.0E-20
miR-30d 955.3 2814.0 2.95 1.0E-20
miR-26a 1122.0 3302.9 2.94 1.0E-20
miR-30a 994.2 2890.0 2.91 1.0E-20
miR-200b 810.9 2314.2 2.85 1.0E-20
miR-181a 399.9 1086.5 2.72 7.5E-11
miR-191 3204.8 7507.6 2.34 1.0E-20
miR-151-5p 938.7 2151.2 2.29 1.0E-20
miR-1246 4537.9 9072.1 2.00 1.0E-20
The microRNAs with a fold-change ≥ 2 and mapped reads ≥1,000 in at least
one condition are shown. The fold change was calculated by normalizing the
reads to the number of mapped reads and the p-values were calculated using
the Likelihood Ratio Test and adjusted using the Benjamini and
Hochberg post-test
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MCF7 cells were treated with DHA. RNA was extracted
from the endothelial cells and the expression levels of these
microRNAs were measured by qRT-PCR. As shown in
Fig. 4a the expression of let-7a, miR-21, miR-23b, miR-27b,
and miR-320b were dramatically increased in the endothe-
lial cells by DHA treatment of the MCF7 cells. A similar
microRNA expression pattern was obseved when DHA-
terated exosomes were directly applied to EA.hy926 cells
(Additional file 3). These results indicate that the micro-
RNAs carried by the DHA-treated breast cancer cell exo-
somes are readily transferred to endothelial cells.
miR-23b, miR-27b, and miR-320b inhibit tube formation
by endothelial cells
To determine which microRNA cargo carried by the MCF7
exosomes might modulate the anti-angiogenesis effects
of DHA we transfected EA.hy926 cells with microRNA
mimics for miR-21, miR-23b, miR-27b, miR-320b, let-7a
or scramble control. microRNA overexpression in the
EA.hy926 cells was confirmed with at least a 10-fold in-
crease in expression as determined by qRT-PCR 48 h
post-transfection. Following microRNA mimic transfection
the cells were plated on matrigel and cultured. Tube forma-
tion by the endothelial cells was quantitated by branch-
point counting (Fig. 4b) and imaged by light microscopy
(Fig. 4c), as we have previously described [32]. As shown,
increased levels of miR-23b, miR-27b, and miR-320b in the
endothelial cells dramatically reduced tube formation by
the endothelial cells, whereas overexpression of let-7a and
miR-21 did not reduce the tube formation, suggesting that
the exosomal microRNAs, miR-23b, miR-27b, and miR-
320b, mediate DHA’s anti-angiogenesis activity.
Co-cultivation of breast cancer cells or microRNA mimic
transfection of miR-23b or miR-320b inhibits pro-
angiogenesis target mRNA expression
Several previously defined and validated target genes of
miR-23b and miR-320b are known to encode proteins
that modulate angiogenesis, including plasminogen acti-
vator (PLAU) [33], angiomotin like-1 (AMOTL1) [34],
neuropilin 1 (NRP1) [31], and v-ets avian erythroblast-
osis virus E26 oncogene homolog 2 (ETS2) [35]. We
asked whether exosome transfer of miR-23b and miR-
320b to endothelial cells would affect expression of these
Fig. 2 Validation of DHA-induced microRNA expression changes in
exosomes secreted from breast cancer cells. MCF10A, MCF7, ZR751,
MDA-MB-231 and BT20 breast cancer cells were plated at a density
of 5x106 cells per 150 mm dish and cultured for 3 days. Cells were
treated with 100 μM DHA for 24 h. Exosomes were collected from
the conditioned media by ultracentrifugcation, total RNA was extracted,
reverse transcribed and amplified by real-time PCR using microRNA
specific primers (n = 3, error bars = SE). The fold change in expression
levels was calculated using the ΔΔCt method. *p < 0.05 by Student’s
t test
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pro-angiogenesis target genes. To address this, we co-
cultured EA.hy926 cells with MCF7 cells for 24 h. As
shown in Fig. 4d, treatment of the co-cultured MCF7
cells with DHA dramatically decreased the expression
of PLAU, AMOTL1, NRP1 and ETS2 in the endothelial
cells. Direct application of microRNA mimics to the
EA.hy926 cells for miR-23b repressed the expression of its
target genes PLAU and AMOTL1 (Fig. 4e) and mimics for
miR-320b repressed the expression of its target genes
NRP1 and ETS2 (Fig. 4f). These results demonstrate that
the DHA-induced changes in the microRNA contents of
breast cancer secreted exosomes, particularly the increase
in miR-23b and miR-320b, can suppress the expression of
pro-angiogenesis microRNA target genes.
Rab27A knockdown reverses DHA-induced exosome-me-
diated microRNA transfer and inhibition of tube
formation by endothelial cells
To confirm that the observed effects of DHA on the endo-
thelial cells are dependent on breast cancer exosome
secretion and contents, we knocked down the expression
of the small Rab GTPase, Rab27A. Rab27A has been
shown to control multivesicular endosome membrane
docking at the plasma membrane and exosome secretion
[36]. The expression of Rab27A was knocked down using
a miR-30 based shRNA entry vector with dsRed2 co-
expression. The shRab27A-dsRed vector was transduced
into MCF7-CD63-GFP and MDA-MB-231-CD63-GFP
cells. Expression of the shRab27A construct was confirmed
Fig. 3 DHA increases exosome secretion from breast cancer cells and reduces tube formation by endothelial cells without affecting VEGF
secretion. a Western blot analysis of CD63 expression in exosomes isolated from MCF7 and MDA-MB-231 cells after treatment with DHA.
Equal volumes of exosome protein lysate were loaded and SDS-PAGE was run under non-reducing conditions. b CD63-GFP tagged exosomes secreted
into cell culture medium from DHA-treated or untreated MCF7 and MDA-MB-231 breast cancer cells were isolated by ultracentrifugation, re-suspended
in PBS and the GFP levels were measured by fluorescent spectrometry, * p < 0.0001 using one-way ANOVA (n = 3). c MCF7 and MDA-MB-231
breast cancer cells were treated with 100 μM DHA for 24 h. The media was removed for exosome isolation and the breast cancer cells that
remained after DHA treatment were counted and are expressed as the average cell number per 106 cells (n = 3, error bars = SE). d MCF7 cells
were treated with 100 μM DHA for 24 h, the exosomes from the treated and untreated cultures were isolated from the culture media by ultracentrifugation
and stained with acridine orange (AO). The AO-labeled exosomes (100 μg) were incubated with EA.hy926 cells (1×104) seeded on ECMatrix
in a 12-well plate for 24 h and imaged with a Perkin Elmer Operetta at 40× magnification, bright field (left) and fluorescence (right), 460 nm excitation
and 650 nm emission. e Approximately 1/10 of the exosomes isolated from a confluent 100 mm plate of DHA-treated or untreated MCF7 cells were
mixed with 1×104 EA.hy926 cells and seeded on ECMatrix in a 96-well plate and incubated for 18 h. Tube formation was visualized with a light
microscope (lower) and counted (upper) *, p < 0.001 using one-way ANOVA (n = 4). f MCF7 cells were treated with 100 μM DHA, 1 mM clofibrate
(CF) or 20 μM troglitazine (Trog) for 24 h and VEGF in the medium was analyzed by ELISA and expressed as pg/ml. *, p < 0.001 using one-way
ANOVA (n = 4-6)
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by detection of dsRed levels by fluorescent microscopy
(Fig. 5a). Knockdown of the Rab27A protein and mRNA
was also confirmed by western blot analysis (Fig. 5b) and
qRT-PCR (Fig. 5c), respectively. As shown in Fig. 5d exo-
some secretion was significantly reduced by Rab27A knock-
down. To determine if the effects of DHA on endothelial
cell tube formation are dependent on Rab27A-mediated
exosome secretion, EA.hy926 cells were seeded on matrigel
and co-cultured with the MCF7 CD63-GFP, shRab27A-
MCF7-CD63, MDA-MB-231 CD63-GFP, or shRab27A-
MDA-MB-231-CD63 cells plated in a transwell insert.
DHA treatment reduced tube formation by the EA.hy926
cells when co-cultured with the wildtype or CD63-GFP
breast cancer cells. However, branch-point formation was
increased by DHA-treatment in the shRab27A co-cultures
(Fig. 5e), suggesting that the anti-angiogenesis effects of
Fig. 4 DHA-induced exosome microRNA transfer from MCF7 cells to endothelial cells alters microRNA expression, endothelial tube formation, and
target mRNA expression. a EA.hy926 cells (2.5×104) were plated in a 24-well plate and MCF7 cells (2×104) were plated in a transwell insert (0.4 μM) and
co-cultured for 24 h. MCF7 cells were treated with 100 μM DHA for 24 h, RNA was extracted and qRT-PCR was performed. The fold change in expression
levels was calculated using the ΔΔCt method. Data in bar graphs represent mean ± SEM (n= 3). EA.hy926 cells were transfected with a scramble control,
let-7a, miR-21, miR-23b, miR-27b, or miR-320b mimics. After 48 h EA.hy926 cells (1×104) were plated on ECMatrix in a 96-well plate and incubated at
37 °C for 16–18 h. Branch points were counted (b) and representative images (c) were taken and under a light microscope (20×). Shown are
the combined triplicate results from three independent experiments. Data in bar graphs represent mean ± SEM (n = 9). *, p < 0.001 using Student’s t
test. d EA.hy926 cells (2.5×104) were seeded on a 24-well plate and MCF7 cells (2×104) were cultured overnight in a transwell insert (0.4 μm). MCF7 cells
in the upper chamber were treated with DHA for 24 h. RNA was extracted from the EA.hy926 cells in the lower chamber and target gene expression
was measured by qRT-PCR. EA.hy926 cells were transfected with a scramble control, miR-23b, or miR-320b mimic. The previously validated
mRNA targets (PLAU and AMOTL1) for miR-23b (e) and (NRP1 and ETS2) miR-320b (f) were measured by qRT-PCR 48 h post-transfection. The
fold change in expression levels was calculated using the ΔΔCt method. Data in bar graphs represent mean ± SEM (n = 3). *, p < 0.05 using
Student’s t test
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DHA are dependent on Rab27A-mediated exosome secre-
tion. To test whether the transfer of miR-23b or miR-320b
occurs with Rab27A knockdown, EA.hy926 cells were
plated on the surface of a 24-well plate and cultured
alone or co-cultured with MCF7 CD63-GFP or shRab27A
MCF7 CD63-GFP cells and treated with DHA for 24 h. As
shown in Fig. 5f, the DHA-induced exosome-mediated
transfer of miR-23 and miR-320b was inhibited by Rab27A
knockdown as compared to CD63-GFP cells. These results
suggest that the anti-angiogenesis effects of DHA on
endothelial cells are dependent on breast cancer exosome
secretion and content transmission.
Discussion
To our knowledge this is the first demonstration that DHA,
a natural anticancer compound, alters breast cancer exo-
some secretion and microRNA contents, which conse-
quently lead to the suppression of endothelial tube
Fig. 5 Rab27A knockdown in breast cancer cells inhibits DHA-induced exosome transfer. The expression of Rab27A was knocked down in MCF7
CD63-GFP and MDA-MB-231 CD63-GFP breast cancer cell lines by transduction with a lentivirus expressing dsRed2 and two different shRNAs
targeting Rab27A. a Bright field (left) and fluorescent microscopic images (right) of CD63-GFP (green), shRab27A-dsRed2 (red) and Hoescht nuclear
stain (blue) (40× magnification). Rab27A protein and mRNA knockdown was confirmed by western blot (b) and qRT-PCR (c). The fold change
in expression levels of Rab27A relative to an endogenous control was calculated using the ΔΔCt method. Data in bar graphs represent mean ± SEM
*, p < 0.001 using Student’s t test. d The quantity of exosomes secreted from breast cancer cells was measured by BCA assay and represented
as the μg/μl of whole exosome per 106 cells, relative to wildtype. Data in bar graphs represent mean ± SEM (n = 2). e MCF7 and MDA-MB-231
cells expressing CD63 or shRab27A-CD63 were grown in a transwell insert (0.4 μm) and co-cultured with EA.hy926 cells plated on ECMatrix for
24 h. Following treatment of the breast cancer cells in the upper chamber with 100 μM DHA for 24 h the number of branch points formed by
the EA.hy926 cells were counted. Data in bar graphs represent mean ± SEM (n = 3-6) *, p < 0.05; **, p < 0.01 using Student’s t test. f MCF7 cells
expressing CD63 or shRab27A-CD63 were grown in a transwell insert (0.4 μm) and co-cultured with EA.hy926 cells plated in a 24-well plate.
Following treatment of the breast cancer cells in the upper chamber with 100 μM DHA for 24 h total RNA was extracted from the EA.hy926
cells, reverse transcribed and expression of miR-23b and miR-320b was measured by qRT-PCR. The fold change in expression levels was calculated
using the ΔΔCt method. Fold-change values are normalized to control sample and expressed relative to no breast cancer cells (−BC). Data in bar
graphs represent mean ± SEM (n = 3) *, p≤ 0.05; **, p < 0.001 using Student’s t test
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formation. In addition to revealing new mechanisms of
DHA’s anticancer action, these novel findings support the
concept that breast cancer exosome signaling can be tar-
geted to inhibit tumor angiogenesis.
The importance of exosomes as mediators of cancer
progression has been realized in recent years [37]. How-
ever, ways to reduce or change their influence on cancer
progression has not been demonstrated. In this study we
have shown that DHA can alter the microRNA contents
and secretion of breast cancer exosomes. We have pro-
vided evidence to show that the microRNA contents of
cancer-derived exosomes can be altered, and that these
changes can influence their biological activity and intercel-
lular communication. These results provide insight into
the future possibility of developing new cancer thera-
peutic strategies targeting exosome secretion and con-
tent transmission.
The anti-angiogenic activity of DHA has been known
for some time [9, 10, 38], however the precise mechanism
is elusive. In this study we have shown that the exosomes
isolated from DHA-treated breast cancer cells were
enriched with microRNAs that target several genes in-
volved in endothelial cell migration, regulation of capillary
formation and angiogenesis. More importantly, application
of these exosomes to endothelial cells inhibited endothelial
tube formation. These results strongly suggest that DHA’s
anti-angiogenesis effects are at least in part mediated
through transfer of exosomes. Because exosomes en-
capsulate and transfer other biologically active proteins,
lipids, and mRNAs, it is also likely that DHA may alter
other contents of breast cancer exosomes, which may
also mediate the anti-angiogenic effects of DHA.
In the present study we showed that co-culture of
endothelial cells with DHA-treated breast cancer cells or
application of microRNA mimics significantly inhibited
tube formation and repressed the expression of pro-
angiogenesis target genes, including PLAU and AMOTL1
for miR-23b and NRP1 and ETS2 for miR-320b. In support
of these findings, a recent study has demonstrated that exo-
somal transfer of miR-320 from diabetic cardiomyocytes to
endothelial cells resulted in inhibition of angiogenesis and
reduction in ETS2 expression [39], thus suggesting that
exosomal transfer of miR-320 may regulate angiogenesis in
other biological model systems.
The mechanism of how DHA might be affecting exo-
some secretion and changes in exosome microRNA
contents is unknown at this time. It is known, however,
that exosomes are enriched in the sphingolipid ceramide,
whose formation is regulated by neutral sphingomyelinase
(nSMase) [40]. It has been demonstrated that exosome se-
cretion can be stimulated by ceramide and inhibited by
treatment with the nSMase inhibitor GW4869 [41]. Over-
expression of nSMase can increase extracellular levels of
microRNAs, whereas treatment with GW4869 microRNA
secretion can be reduced [24]. Another study has shown
that DHA treatment of breast cancer cells in vitro and
through dietary supplementation in vivo induces a 30–
40 % increase in nSMase activity and ceramide formation;
these effects could also be inhibited by addition of GW4869
[42]. Collectively, these studies indicate that DHA may be
involved in regulating exosome secretion and microRNA
encapsulation through ceramide formation. However,
to date no link has been established connecting DHA,
exosomes and microRNA secretion. Here we have provided
evidence that DHA can induce exosome secretion and alter
the microRNA contents of breast cancer exosomes result-
ing in changes in their biological function. Whether this ef-
fect is mediated through nSMase regulation of ceramide
production is yet to be determined.
Conclusions
In conclusion, this study demonstrates that DHA’s anti-
angiogenesis action is highly likely to be mediated
through stimulation of exosome secretion and alteration
of exosome microRNA contents in breast cancer model
systems. These results provide new insight into DHA’s
anticancer action and further support the use of DHA as
an adjuvant for breast cancer therapy.
Methods
Cell culture
The human breast cancer cell lines MCF7, MDA-MB-
231, BT20 and ZR-75-1 were obtained from the American
Type Culture Collection (Manassas, VA). The cells were
cultivated in DMEM medium supplemented with
exosome-depleted 10 % fetal bovine serum (FBS), 100 IU/
mL penicillin and 100 μg/mL streptomycin (Corning/
Mediatech, Inc. Manassas, VA). Exosome depleted FBS
was prepared by pelleting the exosomes by ultracentrifu-
gation at 100,000 × g for 2 h at 4 °C, the resulting super-
natant was filtered through a 0.2 μm pore filter and then
added to cell culture medium. The EA.hy926 endothelial
cell line was kindly provided by Dr. Doris Benbrook (Uni-
versity of Oklahoma Health Sciences Center, Oklahoma
City, OK) and was cultivated in F12-K (Corning/Media-
tech Inc.) medium supplemented with 10 % fetal bovine
serum, 50 mg/mL Heparin (Sigma-Aldrich, St. Louis,
MO), 0.05 mg/mL Endothelial Cell Growth Supplement
(ECGS; Corning/Mediatech Inc.), and 100 IU/mL penicil-
lin and 100 μg/mL streptomycin (Corning/Mediatech
Inc.). Cells were routinely maintained in a humidified
chamber at 37 °C and 5 % CO2.
Preparation and application of DHA
Docosahexaenoic acid was analytical grade (Sigma-Aldrich)
and a stock solution was prepared by dissolving DHA in
molecular grade ethanol at 30 mM and stored at −80 °C
under argon gas. For DHA treatment a 5 mM working
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stock was prepared by dilution with 1.5 mM bovine serum
albumin in PBS before adding to cell culture. The final
concentration of ethanol in the medium was below 0.5 %.
Control cells were treated with vehicle buffer.
Exosome isolation
Exosomes were isolated utilizing a combination of centri-
fugation and ultracentrifugation according to [43] and fil-
tration or the Exoquick-TC reagent (System Biosciences,
Mountain View, CA) following the manufacturer’s
protocol. For ultracentrifugation isolation, conditioned
cell culture media was collected and centrifuged at
10,000 × g for 30 min at 4 °C, to remove cells and large
debris. The supernatant was filtered using a 0.22-μm pore
filter and the exosomes were pelleted at 100,000 × g for
1 h at 4 °C. The exosome pellet was washed with 10 ml of
1X PBS and pelleted again by centrifugation at 100,000 × g
for 1 h at 4 °C. The resulting pellet was either suspended
in 1X PBS for whole exosome applications or further proc-
essed for RNA or protein extraction. Total exosome RNA
was extracted using the TRIzol reagent (Invitrogen/Life
Technologies, Carlsbad, CA) following the manufacturer’s
protocol.
Western blot analysis
Total exosome protein was prepared by re-suspending
the exosomes in RIPA Buffer (50 mM Tris–HCl pH 7.4,
150 mM NaCl, 0.5 % sodium deoxycholate, 1 % NP-40,
and 0.1 % sodium dodecyl sulfate) containing 1 mM
phenlymethylsulfonyl fluoride, 5 μg/ml leupeptin, 2 μg/ml
aprotinin, and 1 μg/ml pepstatin A. About 30–40 μg of
protein from each sample was separated on a 10 % SDS-
PAGE gel, transferred to a PVDF membrane, and blotted
with antibodies against CD63 (Santa Cruz Biotechnology,
Santa Cruz, CA), Rab27A (Abnova, Taiwan) or β-actin
(Sigma-Aldrich, St. Louis, MO).
Electron microscopy and immunogold labeling
Exosomes were fixed in 2 % paraformaldehyde. The fixed
sample was absorbed onto formvar coated copper grids for
20 min in a dry environment. Samples were then fixed in
1 % glutaraldehyde for 5 min. After being rinsed in distilled
water samples were stained with uranyl oxalate for 5 min
followed by methyl cellulose uranyl acetate for 10 min on
ice. Excess liquid was wicked off of the grid using filter
paper, and grids were stored at room temperature until
imaging. For immunogold labeling, exosomes were fixed in
2 % paraformaldehyde. Samples were absorbed onto for-
mvar coated copper grids for 20 min in a dry environment.
Samples were washed with PBS three times. Samples then
underwent four washes in 50 mM glycine followed by a
10 min blocking step. Exosomes were incubated with
CD63 primary antibody for 30 min, and then samples
were washed in washing buffer six times. Samples were
incubated in secondary antibody conjugated to 10 nM
gold particles for 20 min. Finally, samples were washed
in PBS, stabilized with glutaraldehyde, washed in water,
and counter stained with uranyl oxalate and methyl cel-
lulose uranyl acetate. Imaging was done on a Hitachi
H7600 microscope.
CD63 overexpression and Rab27A knockdown
To overexpress GFP-tagged CD63 the lentiviral expression
vector pCT-CD63-GFP was obtained from System Biosci-
ences, Mountain View, CA. To reduce the expression
of Rab27A, shRNAs were cloned into the miR-30 based
shRNA entry vector pEN_TRmiRc2 with dsRed2 co-
expression. pEN_TRmiRc2 was a gift from Iain Fraser
(Addgene plasmid #25750). The following sequences
within the Rab27A 3′UTR were targeted: #1: CCAGCT
CAATGTCTTTGAGTAT and #2: CGCTCAATGTCTTT
GAGTATTA. The resulting fragment was cloned into
the pLenti CMV Puro DEST expression vector, a gift
from Eric Campeau (Addgene plasmid #17452), using
the Gateway LR Clonase II Enzyme (Invitrogen/Life
Technologies, Carlsbad, CA). The lentiviral expression
vectors were used to generate VSVg pseudotyped lentivirus.
Virus production and infection of cells was performed
similarly as before [44]. The 3rd generation packaging
plasmids pMD2.G (Addgene plasmid #12259); pMDL/
RRE g/p (Addgene plasmid #12251), and pRSV-Rev
(Addgene plasmid #12253) were a gift from Didier Trono.
The packaging plasmids were co-transfected with the len-
tiviral expression vector into human embryonic kidney
293 T cells using the polyethylenimine (Polysciences, Inc.
Warrington, PA) transfection method to produce replica-
tion deficient lentivirus. After 48 and 72 h of transfection,
supernatants were pooled, filtered through a 0.45-μm
MCE membrane and concentrated using polyethylene gly-
col (Sigma-Aldrich) [45, 46]. MCF7 and MDA-MB-231
were infected with lentivirus in the presence of 8 μg/ml
polybrene (Sigma-Aldrich). Approximately 48 h post-
infection cells were selected for gene transfer by treating
with 1 μg/ml puromycin (InvivoGen, San Diego, CA).
Fluorescent spectrometry, microscopy and cell imaging
CD63-GFP (copGFP) levels were measured on BioTek
Synergy HT plate reader (BioTek Instruments, Inc.
Winooski, VT) and detected by excitation at 485 nm
and emission at 528 nm. Endothelial cells were analyzed
by fluorescence microscopy using the Operetta High
Content Imaging System (PerkinElmer, Waltham, MA).
Endothelial cells were plated on Matrigel in Cell Carrier-96
plate from (PerkinElmer) at a density of 10,000 cells
per well. Whole exosomes were labeled by combining
1 mL of whole exosomes isolated by ultracentrifugation
with 20 μM acridine orange (AO, Molecular Probes/Life
Technologies). These exosomes were incubated in the
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dark at room temperature for 1 h, diluted in 20 mL of
PBS, and ultracentrifuged at 100,000 × g for 1 h. The
exosome pellet was then resuspended in PBS. AO was
detected by excitation at 460 nm, emission at 650 nm
for red fluorescence.
Endothelial tube formation assay (in vitro angiogenesis)
Endothelial tube formation was measured utilizing the
in vitro Angiogenesis Assay Kit (Millipore, Billerica, MA) as
we have previously described [32]. EA.hy926 (1x104) cells
were resuspended in EBM-2 (Lonza Group, Walkersville,
MD) medium and plated onto the polymerized extracellular
matrix. The formation of endothelial tubes was observed
microscopically and photographed after 17–24 h incuba-
tion. Tube formation was quantified by branch point count-
ing as specified by the manufacturer.
VEGF secretion
Secretion of VEGF from MCF-7 cells was determined
using an ELISA kit as previously reported [32]. Cells were
seeded into 6-well plates at a density of 1x106 cells/well
and treated with clofibrate or troglitazone for 4 h prior to
placement into the hypoxia chamber for 16 h. The culture
medium was then collected, and the level of VEGF in
the medium was analyzed following the manufacturer’s
instructions.
RNA extraction
Total RNA was extracted using the TRIzol reagent
(Invitrogen/Life Technologies) following the manufacturer’s
protocol. RNA concentration was quantitated using the
NanoDrop ND-100 Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE) and the quality was assessed
using the Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA), according to the manufacturer’s protocol.
Small RNA library preparation and next generation
sequencing
A small RNA library was prepared from 100 ng of total
RNA using the TruSeq Small RNA Preparation Kit
(Illumina, San Diego, CA). The MiSeq next generation
sequencer (Illumina) was used to sequence the resulting
cDNA (2x25bp, 50 cycles). The reads were mapped onto
the human genome (hg18 build [47]) and intersected with
microRNAs (mirBase.org [48]) using GeneSifter Software
(PerkinElmer, Santa Clara CA). Reads were normalized
to the mapped reads and significant differences in reads
were determined using the Likelihood Ratio Test and the
Benjamini and Hochberg post-test. A p < 0.05 is consid-
ered significant. P-values close to 0 are represented as
1.0E-20. The RNA sequencing data discussed in this publi-
cation have been deposited in NCBI’s Gene Expression
Omnibus [49] and are accessible through GEO Series
accession number GSE70432 (http://www.ncbi.nlm.nih.-
gov/geo/query/acc.cgi?acc=GSE70432).
Quantitative real-time reverse transcription PCR
For microRNA expression analysis complementary DNA
from 5 ng of total RNA was synthesized by the addition of
a microRNA specific 5X reverse transcription stem-loop
primer and the TaqMan microRNA Reverse Transcription
Kit, according to the manufacturer’s instructions. Real-
Time PCR was performed by diluting the cDNA product in
2X TaqMan Universal Master Mix II (with UNG) and 20X
TaqMan microRNA Expression Assay for each mature
microRNA to be measured: miR-21 (ID:000397), miR-23b
(ID:00400), miR-27b (ID:000409), miR-320b (ID:002844),
and let-7a (ID:000377). All reagents and primers were
from Life Technologies. The small ribonuclear RNA
RNU6B (ID:001093) served as a microRNA expression
normalization control for cellular microRNA expression
analysis. However, we found RNU6B to be unreliable for
exosome microRNA expression normalization, therefore
we used a synthetic Caenorhabditis elegans miR-54 (cel-
miR-54) RNA oligonucleotide (Integrated DNA Technolo-
gies, Coralville, IA) as a spike-in control. Cel-miR-54 has
previously been shown not to affect human microRNA de-
tection [50]. The cel-miR-54 (0.25 nM) oligonucleotide
was spiked into each RNA sample prior to complementary
DNA synthesis and Real-Time PCR was performed using
the TaqMan microRNA assay (ID:001361, Life Technolo-
gies). microRNA target gene expression was measured by
generating cDNA from 200 ng of total RNA using the
iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). The
synthesized cDNA was diluted in 2X iTaq Universal SYBR
Green Supermix (Bio-Rad, Hercules, CA) and combined
with 4uM of each forward and reverse primer. Specific pri-
mer sequences used are as follows NRP1, forward 5′-CCT
TCTGCCACTGGGAACAT-3′ and reverse 5′-TTGCCAT
CTCCTGTGTGATCC-3′; AMOTL1, forward 5′-CGAGG
GACTGAACTAGCCAT-3′ and reverse 5′-AGGGGACCC
TTTCACCG-3′; PRDX1, forward 5′-CTGGTTGAACCCC
AAGCTGATA-3′ and reverse 5′-CAGCTGTGGCTTTG
AAGTTGG-3′; PLAU, forward 5′-CGACTCCAAAGGCA
GCAATGA-3′ and reverse 5′-TGGACACACATGTTCCT
CCATT′3′; ETS2, forward 5′-CTCACCAACAATTCTGG
GACTC-3′ and reverse 5′-CACATCCAGCAAGGACGA
CT-3′; and the normalization control 36B4, forward 5′-AT
CAACGGGTACAAACGAGTCCTG-3′ and reverse 5′- A
AGGCAGATGGATCAGCCAAGAAG-3′. PCR reactions
were run on the Bio-Rad CFX 96 Real-Time PCR (Bio-Rad,
Hercules, CA) instrument under the following conditions:
hold at 95 °C for 10 min, then 40 cycles of 95 °C for 15 s
and 60 °C for 1 min. Relative gene expression was assessed
using the differences in normalized Ct (ΔΔCt method) after
normalization to RNU6B (cellular microRNA) or cel-miR-
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54 (exosome microRNA). Fold changes were calculated
using 2-ΔΔCt.
microRNA mimic transfection
miRIDIAN microRNA mimics (50 nM) were transfected
into endothelial cells using the DharmaFect Duo reagent
(Dharmacon/GE Healthcare, Lafayette, CO) according to
manufacturer’s protocol.
Statistical analysis
All statistical analyses were completed using GraphPad
Prism software (GraphPad Software, Inc. La Jolla, CA).
When appropriate a Student’s t-test or One-way analysis
of variance (ANOVA) with Dunnett’s post-test was used
to determine statistically significant differences among
control and experimental groups, with a p < 0.05 or
lower as the level of significance.
Additional files
Additional file 1: Next generation small RNA sequencing data. This
Excel file contains the microRNA reads and pairwise analysis results for
the control and DHA treated MCF7 cells and exosomes.
Additional file 2: CD63-GFP expression in breast cancer cells. This
file contains microscopic images confirming CD63-GFP expression in
breast cancer cells.
Additional file 3: Transfer of exosome microRNA from MCF7
exosomes to endothelial cells. This file contains microRNA expression data
confirming exosome microRNA transfer from MCF7 exosomes to endothelial cells.
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